Tokuzo Arao

4.7k citations

90 papers · 3.7k indexed · h-index 38

Oncology top 2%
- HER2/EGFR in Cancer Research 13
- Colorectal Cancer Treatments and Studies 9
Cancer Research top 2%
- Cancer Genomics and Diagnostics 9
Hepatology top 5%
- Liver physiology and pathology 7
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 9
- Angiogenesis and VEGF in Cancer 9
- Fibroblast Growth Factor Research 7
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 22

Co-authors: Kazuto Nishio Yoshihiko Fujita Yasuhide Yamada Hideharu Kimura Kazuko Sakai Kazuhiko Nakagawa Isamu Okamoto Hiroyasu Kaneda
Cited by: Oncology Cancer Research Hepatology
Partner nations: Japan United States United Kingdom

In The Last Decade

Tokuzo Arao

90 papers receiving 3.7k citations

Peers

Countries citing papers authored by Tokuzo Arao

Since Specialization

Citations

This map shows the geographic impact of Tokuzo Arao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tokuzo Arao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tokuzo Arao more than expected).

Fields of papers citing papers by Tokuzo Arao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tokuzo Arao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tokuzo Arao. The network helps show where Tokuzo Arao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tokuzo Arao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tokuzo Arao Line = papers co-authored together Tokuzo Arao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma Tomoyuki Nagai,Tokuzo Arao,Kazuto Nishio,Kunio Matsumoto,Satoru Hagiwara,Toshiharu Sakurai,Yasunori Minami,Hiroshi Ida,Kazuomi Ueshima,Naoshi Nishida,Kazuko Sakai,Nagahiro Saijo,Kanae Kudo,Hiroyasu Kaneda,Daisuke Tamura,Keiichi Aomatsu,Hideharu Kimura,Yoshihiko Fujita,Seiji Haji,Masatoshi Kudo	2016	17
2	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kiyoko Kuwata,Erina Hatashita,Haruka Yamaguchi,Kazuko Sakai,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa	2012	73
3	Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation Yoshihiko Fujita,Kenichi Suda,Hideharu Kimura,Kazuko Matsumoto,Tokuzo Arao,Tomoyuki Nagai,Nagahiro Saijo,Yasushi Yatabe,Tetsuya Mitsudomi,Kazuto Nishio	2012	99
4	Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors Isamu Okamoto,Tokuzo Arao,Masaki Miyazaki,Taroh Satoh,Kunio Okamoto,Takuya Tsunoda,Kazuto Nishio,Kazuhiko Nakagawa	2012	13
5	Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor Hidetoshi Hayashi,Takayasu Kurata,Yasuhito Fujisaka,Hisato Kawakami,Kaoru Tanaka,Takafumi Okabe,Masayuki Takeda,Taroh Satoh,Kōji Yoshida,Takuya Tsunoda,Tokuzo Arao,Kazuto Nishio,Kazuhiko Nakagawa	2012	16
6	Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma Tomoyuki Nagai,Tokuzo Arao,Kazuyuki Furuta,Kazuko Sakai,Kanae Kudo,Hiroyasu Kaneda,Daisuke Tamura,Keiichi Aomatsu,Hideharu Kimura,Yoshihiko Fujita,Kazuko Matsumoto,Nagahiro Saijo,Masatoshi Kudo,Kazuto Nishio	2011	101
7	Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma Makoto Nishio,Takeharu Yamanaka,Kazuko Matsumoto,Hideharu Kimura,Kazuko Sakai,Asao Sakai,Takashi Sone,Atsushi Horiike,Fumiaki Koizumi,Kazuo Kasahara,Tatsuo Ohira,Norihiko Ikeda,Nagahiro Saijo,Tokuzo Arao,Kazuto Nishio	2011	5
8	Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure Koichi Azuma,Junji Tsurutani,Kazuko Sakai,Hiroyasu Kaneda,Yasuhito Fujisaka,Masayuki Takeda,Masahiro Watatani,Tokuzo Arao,Taroh Satoh,Isamu Okamoto,Takayasu Kurata,Kazuto Nishio,Kazuhiko Nakagawa	2011	45
9	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors Isamu Okamoto,Hiroyasu Kaneda,Taroh Satoh,Wataru Okamoto,Masaki Miyazaki,Ryotaro Morinaga,Shinya Ueda,Masaaki Terashima,Asuka Tsuya,Akiko Sarashina,Koichi Konishi,Tokuzo Arao,Kazuto Nishio,R. Kaiser,Kazuhiko Nakagawa	2010	79
10	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth Hiroyasu Kaneda,Tokuzo Arao,Kaoru Tanaka,Daisuke Tamura,Keiichi Aomatsu,Kanae Kudo,Kazuko Sakai,Marco A. De Velasco,Kunio Matsumoto,Yoshihiko Fujita,Yasuhide Yamada,Junji Tsurutani,Isamu Okamoto,Kazuhiko Nakagawa,Kazuto Nishio	2010	157
11	Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo Kanae Kudo,Tokuzo Arao,Kaoru Tanaka,Tomoyuki Nagai,Kazuyuki Furuta,Kazuko Sakai,Hiroyasu Kaneda,Kazuko Matsumoto,Daisuke Tamura,Keiichi Aomatsu,Marco A. De Velasco,Yoshihiko Fujita,Nagahiro Saijo,Masatoshi Kudo,Kazuto Nishio	2010	31
12	Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition Wataru Okamoto,Isamu Okamoto,Takeshi Yoshida,Kunio Okamoto,Ken Takezawa,Erina Hatashita,Yuki Yamada,Kiyoko Kuwata,Tokuzo Arao,Kazuyoshi Yanagihara,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	2010	58
13	De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer Masayuki Takeda,Isamu Okamoto,Yoshihiko Fujita,Tokuzo Arao,Hiroyuki Ito,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	2010	62
14	Enhanced expression of nuclear factor I/B in oxaliplatin‐resistant human cancer cell lines Eiji Kashiwagi,Hiroto Izumi,Yoshihiro Yasuniwa,Ryoko Baba,Yoshiaki Doi,Akihiko Kidani,Tokuzo Arao,Kazuto Nishio,Seiji Naito,Kimitoshi Kohno	2010	28
15	Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition Daisuke Tamura,Tokuzo Arao,Kaoru Tanaka,Hiroyasu Kaneda,Kunio Matsumoto,Kanae Kudo,Keiichi Aomatsu,Yoshihiko Fujita,Takashi Watanabe,Nagahiro Saijo,Yoshikazu Kotani,Yoshihiro Nishimura,Kazuto Nishio	2010	48
16	mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells Kunio Matsumoto,Tokuzo Arao,Kaoru Tanaka,Hiroyasu Kaneda,Kanae Kudo,Yoshihiko Fujita,Daisuke Tamura,Keiichi Aomatsu,Tomohide Tamura,Yasuhide Yamada,Nagahiro Saijo,Kazuto Nishio	2009	114
17	Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS Kunio Matsumoto,Chikako Shimizu,Tokuzo Arao,Masashi Andoh,Noriyuki Katsumata,Tsutomu Kohno,Kan Yonemori,Fumiaki Koizumi,Hideyuki Yokote,Kenjiro Aogi,Kenji Tamura,Kazuto Nishio,Yasuhiro Fujiwara	2009	20
18	EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line Junya Fukai,Hideyuki Yokote,Ryuya Yamanaka,Tokuzo Arao,Kazuto Nishio,Toru Itakura	2008	113
19	N‐Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor Kunio Matsumoto,Hideyuki Yokote,Tokuzo Arao,Mari Maegawa,Kaoru Tanaka,Yoshihiko Fujita,Chikako Shimizu,Toshiaki Hanafusa,Yasuhiro Fujiwara,Kazuto Nishio	2008	75
20	Catastrophic Intraabdominal Bleeding Due to Rupture of Pancreaticoduodenal Artery Aneurysm: Successful Transcatheter Arterial Embolization Tokuzo Arao,Etsushi Ishida,Shinichi Nishina,Hiromichi Yamane,Masayasu Adachi,Takayuki Sunayama,Seiyuu Suzuki,Tsutomu Katoh	2003	9

About Tokuzo Arao

Tokuzo Arao is a scholar working on Cancer Research, Oncology and Hepatology, having authored 90 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), HER2/EGFR in Cancer Research (13 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Angiogenesis and VEGF in Cancer (9 papers), Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (9 papers), Fibroblast Growth Factor Research (7 papers) and Liver physiology and pathology (7 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (771 citations) and Hepatology (264 citations). Tokuzo Arao has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kazuto Nishio, Yoshihiko Fujita, Yasuhide Yamada, Hideharu Kimura, Kazuko Sakai, Kazuhiko Nakagawa, Isamu Okamoto, Hiroyasu Kaneda, Nagahiro Saijo and Kaoru Tanaka.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact